Nasdaq
$61.65▼ 0.10%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $5.44BShares out 88.2M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
31- 5d agoAfter-hours26.10.20 05:304Ownership#●●●
CG Oncology, Inc.
Insider Isabel Kalofonos of CG Oncology filed a Form 4 report regarding changes in beneficial ownership of securities as of October 15, 2026. This filing serves as a standard disclosure of executive stock holdings.…more
$61.65-0.10%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 5d agoAfter-hours26.10.20 05:304Ownership
CG Oncology, Inc.
Leonard E. Post, an insider at CG Oncology, reported a change in beneficial ownership of company securities via SEC Form 4 on October 15, 2026. This filing serves as a routine disclosure regarding the insider's stock holdings.…more
$61.65-0.10%vs prev closeView filingShare - 5d agoAfter-hours26.10.20 05:153Ownership
CG Oncology, Inc.
Isabel Kalofonos, an officer or major shareholder of CG Oncology, has filed a Power of Attorney authorizing designated representatives to handle SEC filings on her behalf. This filing facilitates the preparation and submission of Form ID and Forms 3, 4, and 5 as required under Section 16 of the Exchange Act.…more
$61.65-0.10%vs prev closeView filingShare
30 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 9.2Pre-market26.09.02 21:00#●●●#●●●
CG Oncology to Participate in September Investor Conferences
CG Oncology announced that its leadership will participate in fireside chats at upcoming Cantor Fitzgerald and Morgan Stanley healthcare conferences. These events serve as platforms for corporate updates but do not contain new material financial disclosures.…more
$61.65-0.10%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 8.6Pre-market26.08.06 21:15
●●●●●●●● ●●●●● ●●●●●●
CG 온콜로지는 2분기 실적과 함께 방광암 치료제 크레토스티모진의 임상 3상 순항 및 연내 BLA 제출 계획을 발표했습니다. 약 10억 달러의 현금 보유고를 통해 2029년까지 안정적인 운영 자금을 확보하며 임상 개발에 집중하고 있습니다.…more
$61.65-0.10%vs prev close - 7.27After-hours26.07.28 07:45
●●●●●●●● ●●●●● ●●●●●●
CG 온콜로지가 방광암 치료제 크레토스티모진의 임상 3상에서 우수한 치료 효과와 안전성을 입증하며 주요 의학 저널에 결과를 게재했습니다. 이번 임상 성공으로 향후 FDA 승인 및 방광암 치료 패러다임 변화에 대한 기대감이 커지고 있습니다.…more
$61.65-0.10%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report